drugset / Trial / NCT05491356

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

NCT05491356

Phase 4 Completed 40 enrolled Hamilton Health Sciences Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the utility of tissue plasminogen activator (tPA) in the clearance of chronic subdural hematomas (CSDH). Intra-catheter tPA will be administered during surgical procedure and allowed to break down blood clot to assist with removal/drainage during twist drill craniostomy procedure.

Timeline

Start
2023-05-11
Primary completion
2024-03-30
Completion
2024-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 1 mg/ml Other

Indications